Xueyong Lou

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 3

Top Topics

Peritoneal Dialysis

Coronary Artery Disease

Cardiovascular Events

Patient Reported

Top Venues

DNA and cell biology

This page only lists publications with an associated author ORCID identifier.

Publications

Yanfen Liu, Dongying Nie, Xueyong Lou
The Cardiovascular Benefits of Glucagon-Like Peptide-1 Receptor Agonists as Novel Diabetes Drugs Are Mediated via the Suppression of miR-203a-3p and miR-429 Expression. DNA and cell biology 43 (8) (2024)
Yanfen Liu, Dongying Nie, Xueyong Lou
The Cardiovascular Benefits of Glucagon-Like Peptide-1 Receptor Agonists as Novel Diabetes Drugs Are Mediated via the Suppression of miR-203a-3p and miR-429 Expression. DNA and cell biology (2024)
Yanfen Liu, Dongying Nie, Xueyong Lou
The Cardiovascular Benefits of Glucagon-Like Peptide-1 Receptor Agonists as Novel Diabetes Drugs Are Mediated via the Suppression of miR-203a-3p and miR-429 Expression. DNA and cell biology 43 (8) (2024)